Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ClinPharm Consulting Renamed to Kinetigen

Published: Thursday, February 07, 2013
Last Updated: Thursday, February 07, 2013
Bookmark and Share
Corporate name changed to establish a unique brand under Kinetigen.

ClinPharm Consulting, LLC (ClinPharm) has announced that the company is changing its name to Kinetigen, Inc., effective February 1, 2013.

All management, scientific, and operational components of Kinetigen remain the same as under ClinPharm, including the consulting firm’s focus on clinical pharmacology and pharmacokinetics.

The change to Kinetigen is a reflection of the impact that the company has made in the pharmaceutical industry and its evolution into a leading consulting firm in clinical pharmacology and pharmacokinetics.

In changing the company name, executive management determined that it was essential to develop a brand that will be easily identifiable and associated with the expertise and value that the company and its industry-leading consultants provide to clients.

“I’m thrilled to continue to build upon ClinPharm Consulting’s reputation and consultancy under our new name of Kinetigen” said Geoffrey Banks, Ph.D., Kinetigen President and CEO, adding, “The launch of Kinetigen is the keystone of our strategic growth initiative that will solidify our position as the go-to resource for clinical pharmacology and pharmacokinetics in the pharmaceutical industry”.

The consulting firm has grown organically over the past 5 years since the company was founded and recently added senior level consultants such as David Y. Mitchell, Ph.D., immediate past President of the American Association of Pharmaceutical Scientists (AAPS), Mark Sale, MD, former Global Director of Modeling and Simulation at GlaxoSmithKline (GSK), and Mark Bush, Ph.D., former Director of Pharmacokinetics at GSK.

“All of our services remain the same with the transition to Kinetigen,” said Bill Wargin, Ph.D., Kinetigen Executive Vice President & Chief Scientific Officer.

Dr. Wargin further explained “We have enhanced our SOPs and working practices, implemented more quality control procedures, and strengthened our training processes to ensure the highest quality product and services continue under Kinetigen that our clients have come to expect”.

Kinetigen’s services include:
• Rapid & robust pharmacokinetic analysis including non-compartmental, compartmental, and population pharmacokinetic methods with industry standard software (WinNonlin, NONMEM, Monolix, and NLME)
• Good Laboratory Practice (GLP) toxicokinetic analysis for determination of toxicokinetic parameters (including in-house QA capabilities and validated pharmacokinetic/ toxicokinetic analysis software)
• Unmatched interpretation of pharmacokinetic data from leading industry experts in pharmacokinetics
• Innovative model based drug development
• Clinical trial simulations
• Authoring clinical pharmacology and pharmacokinetic sections of regulatory submissions
• Assistance with regulatory briefing documents and meetings (e.g., FDA Pre-IND, EoP1, EoP2, pre-NDA, Type C meetings, etc.)
• Horizontal strategic planning across all phases of drug development
• Intelligent design of clinical studies from experts in clinical pharmacology and pharmacokinetics, including authoring clinical trial protocols and study reports
• Due diligence assessment for potential licensing of compounds


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!